{
  "docId": "019dd923-5ca1-7489-b636-bc879d1b6d64",
  "docSlug": "17680cec2cbd3510",
  "documentTitle": "Accelerated Access Review UK Mapping",
  "authorId": "Deloitte",
  "authorName": "Deloitte",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.333,
  "pageNumber": 34,
  "pageCount": 109,
  "prevPage": 33,
  "nextPage": 35,
  "slideType": "pain_points",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a list-based structure to detail specific industry-public sector friction points.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "icon_grid",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b636-bc879d1b6d64/34",
  "deckHref": "/decks/019dd923-5ca1-7489-b636-bc879d1b6d64",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b636-bc879d1b6d64.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b636-bc879d1b6d64#slide-34",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Our research highlighted three key challenges in national reimbursement for early adoption of innovative therapeutic medicines.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-ba8c-7422-853d-369e122986b9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "list",
      "text": "Evidence requirement: Evidence requirements for pricing and reimbursement are not typically considered by Industry during earlier stages of development activity, resulting in iteration of the assessment process or failure to demonstrate sufficient value.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0c654c0-774d-4422-968d-6af327024ae3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.9,
        "x": 0.04,
        "y": 0.42
      },
      "kind": "list",
      "text": "Different definitions of value: Industry and public sector are misaligned on the question of a drug's value, e.g., Industry disagrees on the methodologies applied by NICE and other HTA bodies; some public sector parts consider NICE cost per QALY too high.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dc00777c-1e03-42fc-a8fc-3cd4c5d6c1eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.9,
        "x": 0.04,
        "y": 0.61
      },
      "kind": "list",
      "text": "Misalignment of stakeholder objectives: Misalignment of objectives between NICE and other stakeholders (e.g. NHS England, patient groups and Industry) over strategic priorities and technology implementation, leading to low or slow adoption.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f223d9b8-5bee-43ae-8ee1-df12a3e047a4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.04,
        "y": 0.11
      },
      "kind": "paragraph",
      "text": "Our research highlighted three key challenges in national reimbursement for early adoption of innovative therapeutic medicines",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e8bc27e-219a-48af-b6a4-e92067ef7541",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.04,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Source: Stakeholder interviews, workshops and Deloitte analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0cbaaac4-2c6b-4199-a16d-8e450018aea8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.5,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "National Reimbursement: Key Challenges",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "576ceb09-8880-4959-83e6-7e2df458944d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem-Agitate-Solve (PAS)",
      "slug": "problem-agitate-solve-pas",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "e659a676-3deb-480d-9533-31fec5c29101",
      "evidence": "list/bullet: Different definitions of value: Industry and public sector are misaligned on the question of a drug's value, e.g., Industry disagrees on the methodologies applied by NICE and other HTA bodies; some public se",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 109,
      "from": 21,
      "beatId": "4bae8ed9-97e4-4ca8-988f-171e64b0598d",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document proposes solutions to address the challenges, including streamlining development pathways and improving regulation.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 109,
      "from": 21,
      "name": "Mece Breakdown",
      "slug": "40-mece-breakdown",
      "bestFor": "Problem structuring, ensuring completeness, strategic analysis",
      "matchId": "575c67ea-abbb-4bd3-80bc-943f97973ed4",
      "evidence": "The document proposes solutions to address the challenges, including streamlining development pathways and improving regulation.",
      "position": 1,
      "objective": "How can the NHS improve access to medical innovations?",
      "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage",
      "confidence": 0.7,
      "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}